Elkhorn Investments LLC lowered its stake in shares of Stryker Corporation (NYSE:SYK) by 6.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,180 shares of the medical technology company’s stock after selling 546 shares during the period. Elkhorn Investments LLC’s holdings in Stryker Corporation were worth $1,199,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Bollard Group LLC increased its stake in shares of Stryker Corporation by 0.4% during the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 3 shares during the last quarter. Assetmark Inc. increased its stake in shares of Stryker Corporation by 0.3% during the 1st quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock worth $168,000 after purchasing an additional 4 shares during the last quarter. Blue Chip Partners Inc. increased its stake in shares of Stryker Corporation by 0.3% during the 1st quarter. Blue Chip Partners Inc. now owns 1,775 shares of the medical technology company’s stock worth $234,000 after purchasing an additional 6 shares during the last quarter. Guardian Life Insurance Co. of America increased its stake in shares of Stryker Corporation by 0.8% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock worth $158,000 after purchasing an additional 9 shares during the last quarter. Finally, FineMark National Bank & Trust increased its stake in shares of Stryker Corporation by 0.4% during the 2nd quarter. FineMark National Bank & Trust now owns 3,878 shares of the medical technology company’s stock worth $538,000 after purchasing an additional 15 shares during the last quarter. Institutional investors own 74.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/10/14/stryker-corporation-syk-shares-sold-by-elkhorn-investments-llc.html.

Stryker Corporation (NYSE:SYK) opened at 146.69 on Friday. Stryker Corporation has a 52-week low of $106.48 and a 52-week high of $149.23. The stock’s 50 day moving average is $142.96 and its 200-day moving average is $140.48. The stock has a market capitalization of $54.87 billion, a price-to-earnings ratio of 32.74 and a beta of 0.80.

Stryker Corporation (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.51 by $0.02. The firm had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period in the prior year, the company posted $1.39 earnings per share. Equities research analysts anticipate that Stryker Corporation will post $6.45 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be paid a $0.425 dividend. The ex-dividend date is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.16%. Stryker Corporation’s dividend payout ratio (DPR) is presently 37.95%.

Several equities research analysts have recently issued reports on SYK shares. BMO Capital Markets restated a “hold” rating and set a $140.00 price target on shares of Stryker Corporation in a research note on Tuesday, July 11th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Stryker Corporation in a research note on Monday, June 19th. Cantor Fitzgerald started coverage on shares of Stryker Corporation in a research note on Thursday, June 29th. They set a “neutral” rating and a $153.00 price target for the company. Morgan Stanley restated an “overweight” rating and set a $160.00 price target (up previously from $155.00) on shares of Stryker Corporation in a research note on Monday, July 10th. Finally, Jefferies Group LLC restated a “hold” rating and set a $132.00 price target on shares of Stryker Corporation in a research note on Friday, June 30th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $146.78.

In related news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the transaction, the insider now directly owns 88,207 shares of the company’s stock, valued at $12,909,976.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Graham A. Mclean sold 1,124 shares of the firm’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the transaction, the insider now directly owns 8,983 shares of the company’s stock, valued at $1,313,853.58. The disclosure for this sale can be found here. Corporate insiders own 7.40% of the company’s stock.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.